Earnings Call Intelligence Subscribe
Home › Call Sheets › BIIB › Q2'26
Call sheet · Q2'26

Biogen (BIIB)

Q2'26 earnings call · held July 29, 2026 · compared with the Q1'26 call · management-credibility review
4/12
Disclosure score
2 high, 4 medium, 1 low flags
Financial quality
Bottom line
The market will focus on the modest 3% top‑line lift, but the real story is the **$3.6 B cash drain and $5.3 B debt surge** that leaves Biogen with a thin liquidity cushion. Management touts a thriving growth portfolio and a new $250 M synergy target, yet the binding constraint is the debt‑service burden and the need to convert the high‑margin anti‑CD20 royalty stream into a sustainable revenue engine. If the synergy target or royalty growth stalls, cash‑flow pressure will force a slowdown in R&D spend and jeopardize upcoming readouts. My view flips if free cash flow falls below $300 M in Q3 or if the $250 M synergy target is not on track.

The 30-second version

  • Sleeper story: Anti‑CD20 royalty engine now a $0.5 B revenue pillar
  • Obvious headline - Q2 revenue up modestly, but the real story is the post‑Acquisition cash drain
  • Red flag: key metrics vanished and new “run‑rate synergies” appeared without a denominator

What changed this quarter

MetricQ1'26Q2'26Change
Total Revenue$2.5 B (↑2% YoY)$2.7 B (↑3% YoY)+$200 M (+8% QoQ)
Growth Portfolio Revenue$851 M (↑12% YoY)≈$1.0 B (↑24% YoY, ↑25% QoQ)+~$150 M (+18% YoY)
Cyphovry Revenue (Apellis)N/A (not reported)$162 M (↑8% YoY & QoQ)New line‑item
Empaveli Revenue (Apellis)N/A (not reported)$46 M (↑123% YoY, ↑12% QoQ)New line‑item
Anti‑CD20 RoyaltiesN/A (not disclosed)$514 M (↑10% YoY)New high‑margin revenue stream
Free Cash Flow$594 M$408 M-$186 M (-31%)
Cash & Marketable Securities$4.7 B$1.3 B-$3.4 B (‑72%)
Net Debt$1.5 B$6.8 B+$5.3 B (+353%)
Non‑GAAP Cost‑of‑Sales % of Revenue21%22%+1 ppt
Non‑GAAP Core OpEx (incl. Apellis)$1.1 B (YoY +20%)≈$1.32 B (implied 20% YoY increase)+~$220 M

Accountability tracked

6 new promises made5 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full BIIB Q2'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.